NetworkNewsBreaks – Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Obtains Orphan Drug Designation for Fragile X Syndrome Treatment
Marinus Pharmaceuticals (NASDAQ: MRNS) this morning said that the FDA has granted Orphan Drug Designation to the company’s CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome, the most common genetic cause of autism, which is caused by a mutation in the FMR1 gene. This designation provides Marinus with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act filing fees. “We are pleased to receive Orphan Drug Designation from the…







